EGFR and infection: Compared with US Food and Drug Administration–approved EGFR-targeting mAbs, including cetuximab and panitumumab, rash, pruritus, and other skin toxic effects were less frequently observed during treatment with MRG003 than what has been reported for cetuximab or panitumumab.10 Two deaths were associated with febrile neutropenia, subsequent infections, and a cascade of events, which were most likely associated with monomethyl auristatin E, suggesting that the hematological toxic effects of MRG003 should be monitored closely and controlled in clinical practice.